MHLW Approves Asahi Kasei’s Recomodulin Among Others
This article was originally published in PharmAsia News
Among drugs approved by Japan's Ministry of Health, Labor and Welfare on Jan. 25 is Asahi Kasei Pharma's Recomodulin (recombinant thrombomodulin), the world's first recombinant thrombomodulin drug for treatment of disseminated intravascular coagulation. Other notables are Bayer's kidney cancer drug Nexavar and Zevalin Yttrium IV Set, a monoclonal antibody combined with radioisotope Yttrium, also developed by Bayer
You may also be interested in...
The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.